Compare
Tonix Pharmaceuticals Holding Corp. vs Roivant Sciences Ltd. vs Alumis Inc. vs Earth Science Tech, Inc.
| Latest fiscal year | Tonix Pharmaceuticals Holding Corp. TNXP | Roivant Sciences Ltd. ROIV | Alumis Inc. ALMS | Earth Science Tech, Inc. ETST |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-03-31 | 2025-12-31 | 2026-03-31 |
| Revenue | $13.11M | $8.26M | $24.05M | $35.70M |
| Revenue growth (YoY) | +29.8% | -71.6% | n/a | +7.8% |
| Gross margin | 49.3% (computed) | n/a | n/a | 71.4% |
| Operating margin | -959.1% | n/m | n/m | n/a |
| Net margin | -946.2% | n/m | n/m | 10.2% |
| Net income | -$124.02M | -$299.77M | -$243.32M | $3.63M |
| EPS (Diluted) | -$14.57 | -$0.54 | -$2.86 | $0.012 |
| Operating cash flow | -$99.84M | -$750.35M | -$369.52M | $1.94M |
| Free cash flow | -$103.21M | -$758.56M | -$370.18M | $1.18M |
| Cash & equivalents | $207.64M | $1.42B | $89.67M | $796.8K |
| Total assets | $277.17M | $5.71B | $411.94M | $8.97M |
| Total liabilities | $32.02M | $416.27M | $110.64M | $1.93M |
| Shareholders' equity | $245.15M | $4.53B | $301.30M | $7.01M |
| Return on year-end equity | -50.6% | -6.6% | -80.8% | 51.8% |
| Shares outstanding | 12.79M | 720.35M | n/a | 291.32M |
Revenue, most recent five fiscal years
| Fiscal year | Tonix Pharmaceuticals Holding Corp. | Roivant Sciences Ltd. | Alumis Inc. | Earth Science Tech, Inc. |
|---|---|---|---|---|
| Latest | $13.11M Ended 2025-12-31 | $8.26M Ended 2026-03-31 | $24.05M Ended 2025-12-31 | $35.70M Ended 2026-03-31 |
| 1 year earlier | $10.09M Ended 2024-12-31 | $29.05M Ended 2025-03-31 | n/a | $33.12M Ended 2025-03-31 |
| 2 years earlier | $7.77M Ended 2023-12-31 | $32.71M Ended 2024-03-31 | n/a | $11.95M Ended 2024-03-31 |
| 3 years earlier | n/a | $31.53M Ended 2023-03-31 | n/a | $48.5K Ended 2023-03-31 |
| 4 years earlier | n/a | $55.29M Ended 2022-03-31 | n/a | $14.1K Ended 2022-03-31 |